Stalevo (carbidopa/levodopa and entacapone): Increased Risk for Cardiovascular Events
Neurology and Cardiology healthcare personnel are informed by the FDA that clinical trial data suggest that patients taking Stalevo (carbidopa/levodopa and entacapone) may be at greater cardiovascular risk than patients taking carbidopa/levodopa (Sinemet). Background of Stalevo Stalevo and Sinemet are drugs considered as effective for the symptoms of Parkinson’s disease. Compared to treatment with carbidopa/levodopa [...]
Read more
Recent Comments